Rentokil Initial's North America Problem Deepens as Morgan Stanley Steps Back

Morgan Stanley downgraded Rentokil to Equal Weight and cut its price target to 420 pence, citing North American competition and private equity pressure.

Morgan Stanley has turned more cautious on Rentokil Initial, downgrading the British pest-control group from "Overweight" to "Equal Weight" on Tuesday and trimming its price target by 16%, from 500 to 420 pence. The move reflects mounting competitive pressure in North America, the company's most important market.

Investors took the revision poorly. The stock slipped 2.1% to EUR 3.51 during the session, extending a bruising stretch that has now erased 32% of its value since the start of the year. Tuesday's decline also pushed the shares to a fresh 52-week low, with no company-specific news behind the drop — a sign that the broader downtrend of recent days simply continues to weigh on sentiment. Trading floors have been quiet on the buy side, and no overarching catalyst emerged to spark a rebound.

Private equity reshapes the bidding landscape

At the heart of Morgan Stanley's more guarded stance is a structural shift in the US pest-control industry. For years, large incumbents called the shots, fueling growth by steadily acquiring smaller regional operators. That playbook is being rewritten by deep-pocketed private equity investors, who have turned into aggressive bidders.

According to Morgan Stanley, financial-sponsor-backed operators now generate more than 16% of revenue among the 100 largest US industry players — up from just 1% a decade ago. Over the past few years, this group has also captured more than half of all deals in the sector. The upshot for Rentokil: acquisition targets have become markedly more expensive, forcing the company to pump the brakes on expansion. Management cut its forecast for acquisition spending this year from roughly USD 200 million to USD 120 million.

Losing ground on new customers and margins

Changing customer behavior adds another layer of difficulty. Automated systems and digital search queries increasingly determine how contracts are awarded, creating operational headaches for established providers. A Morgan Stanley study illustrates the shift: among leading recommendations generated by AI language models in the US, nearly four-fifths of mentions went to independent operators, while Rentokil appeared in just 7% of cases.

Profitability tells a similar story. In fiscal 2025, Rentokil's adjusted EBITA margin stood at 15.5%, well behind US rival Rollins at 22.4%.

A portfolio trim — and a vote of no confidence

On the corporate front, management initiated a portfolio move on September 22, agreeing to sell SOLitude Lake Management, LLC and the Vertex Aquatic Solutions business to private equity firm Bain Capital. The agreed price is USD 230 million on a cash- and debt-free basis. The disposal sheds peripheral water-management activities, part of an effort to exit operations outside the core business and free up capital. After taxes, Rentokil expects net cash proceeds of around USD 180 million. Completion hinges on antitrust clearance under the Hart-Scott-Rodino process, with management targeting early in the fourth quarter of 2026.

Markets gave the divestment only a brief nod. Confidence remains subdued, and participants are keeping their focus squarely on the earnings power of the remaining core divisions.

A buy rating that failed to stick

Analysts elsewhere have offered a more upbeat view, though it has done little to break the downward pressure. Investec upgraded the stock from "Hold" to "Buy" on September 23, setting a price target of 400 GBp. Media reports noted a short-lived rally on the back of the upgrade, but those gains were fully surrendered afterward, and no lasting stabilization materialized.

What's next

Morgan Stanley sees limited scope for a re-rating in the near term. CEO Mike Duffy faces a lengthy restructuring effort to sharpen organizational efficiency and defend the company's position in the US market. Concrete clues on current trading are due soon: Rentokil Initial has scheduled its third-quarter trading update for October 22, 2026. Morgan Stanley flags the risk of a subdued update that could further test shareholders' patience.